Skip to main content

Table 1 Individual values for tumor glucose uptake and metabolic tumor volumes at baseline and follow-up

From: 18F–FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma

Number

Groupa

TTLBaseline

TTLFollow-Up

∆TTL

VolumeBaseline (mm3)

VolumeFollow-up (mm3)

∆Volume (mm3)

1

T

5.63

4.83

−0.79

296.0

311.4

15.4

2

T

4.80

3.13

−1.67

86.8

50.4

−36.4

3

T

5.90

5.26

−0.64

56.1

162.7

106.6

4

T

3.72

2.65

−1.07

155.9

417.9

262.0

5

T

3.94

3.88

0.06

142.5

433.7

291.2

6

T

4.57

3.02

−1.55

230.8

185.2

−45.6

7

T

4.61

2.90

−1.71

112.8

78.2

−34.6

8

T

3.69

2.40

−1.29

162.7

118.0

−44.7

9

T

3.11

2.52

−0.59

332.0

392.0

60.0

10

T

3.59

2.46

−1.13

171.3

161.7

−9.6

11

T

4.14

2.93

−1.21

120.0

80.6

−39.4

12

T

2.57

2.29

−0.28

66.2

147.8

81.6

Mean ± SDb

T

4.19 ± 0.97

3.19 ± 0.97

−1.00 ± 0.53

161.1 ± 86.5

211.6 ± 139.4

50.5 ± 117.9

13

C

4.34

4.06

−0.28

96.9

344.0

247.1

14

C

3.07

5.13

2.06

519.1

1192.3

673.2

15

C

5.62

5.50

−0.12

213.0

616.1

403.1

16

C

2.88

3.95

1.07

140.1

329.1

189.0

17

C

4.02

4.13

0.11

222.6

597.8

375.2

18

C

3.31

5.25

1.94

165.1

511.0

345.9

19

C

3.50

5.45

1.95

115.6

421.3

305.7

20

C

2.71

4.73

2.02

392.5

866.5

474.0

21

C

3.81

2.72

−1.09

96.0

283.1

187.1

Mean ± SDb

C

3.70 ± 0.90

4.55 ± 0.91

0.85 ± 1.21

217.9 ± 145.8

573.5 ± 294.7

355.6 ± 153.3

  1. aT = therapy group; C = control group
  2. bSD = standard deviation